A phase 2 trial of zimberelimab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Nataliya Uboha, active and no longer recruiting.
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) is a phase 2 interventional study registered as NCT06048133 by Nataliya Uboha, with a registry enrolment figure of 33 participants, started 2024-03-08 and due to reach its primary completion in 2026-12. Interventions recorded: Gemcitabine, Cisplatin, Zimberelimab, Quemliclustat. Conditions listed: Biliary Tract Carcinoma, Cholangiocarcinoma, Bile Duct Cancer. Sites: United States. No results are recorded here; the registry entry is the source.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.